Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Rhea-AI Summary

Astria Therapeutics, Inc. (ATXS) to present final Phase 1a healthy subject data for STAR-0215 at AAAAI Annual Meeting

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present a poster titled, “Updated Results from a Phase 1a Trial of STAR-0215 for Hereditary Angioedema” at 3:15pm EST in the Convention Center, Level 2, Hall D, poster number 032.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220427055/en/

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is the ticker symbol for Astria Therapeutics, Inc.?

The ticker symbol for Astria Therapeutics, Inc. is ATXS.

What type of therapies does Astria Therapeutics focus on developing?

Astria Therapeutics focuses on developing life-changing therapies for allergic and immunological diseases.

Who will present the final STAR-0215 Phase 1a healthy subject data at the AAAAI Annual Meeting?

Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present the data.

Where and when will the presentation take place?

The presentation will take place at the AAAAI Annual Meeting in Washington, D.C., on February 23, 2024, at 3:15pm EST.